Ruti Aga's Six-Year Ban: Methylprednisolone Is Not an Anabolic Steroid, and That Is the Legal Hinge of This Case

The number nobody looked at

The Athletics Integrity Unit statement released on Thursday carries two figures and implies a third. Two years for the presence of a prohibited substance. Four years for tampering. Six years in total, running from 10 September — the very date her provisional suspension began. Ruti Aga's sample was collected after she won a half marathon in China in March. The substance was methylprednisolone.

Much of the coverage described it as a 'prohibited steroid' and repeated that WADA classes it as performance-enhancing. That sentence is technically wrong, and in this case the error is not a small one. Methylprednisolone is not an anabolic steroid — not class S1 on the WADA Prohibited List. It is a glucocorticoid, class S9. Under the current List, S9 glucocorticoids are prohibited in-competition only, and only by injection, oral or rectal route.

So the pivot of this case is not 'steroid use.' It is route and timing. A therapeutic knee injection given out-of-competition is entirely lawful. It becomes a violation only if residues show up inside the competition window. A real decision turns on that distinction, and the headline did not.

Context: the March race and a chain of paper

The facts, briefly. Aga won a half marathon in China in March. The source gives no race name, no mark, no splits, no field depth. We know she won and that the sample came from that race. The explanation offered was that the drug was taken to treat a knee injury. What the investigation surfaced is a different story: the 'doctor' who issued the prescription was a family member with no medical registration; the clinic named on the prescription does not exist; and the defence claimed an 'old prescription pad from a former workplace' — which that clinic has explicitly disowned.

Three independent verification failures in one document. That is not a filing slip; it is the signature of an athlete operating without a credentialed team physician. I have watched such paper chains before. Through the post-2026 Commonwealth Games period and the CAS-confirmed bans that followed the 2026 tests, one habit hardened: first the ledger, then the legend. Write the date, name the mechanism, and before you type a mark into the record book, check whether the paperwork closed. In Aga's case the paperwork did not close. It became the case.

One thing the source does not say but the rules imply: the result and prize money from the competition where the sample was collected are normally annulled. That is standard AIU practice. The 2026 Tokyo Marathon title, however, predates that date and is not automatically void. The source states no disqualification scope at all — and that gap is where a half-report and a filed record part ways.

Core: the arithmetic of 2 + 4 = 6, and a defence that was available

Six years is not an anomalous sanction. That is exactly what makes it unsettling.

Two years for presence. That is the Code's standard sanction where the substance is a Specified Substance and intent is not proven — the panel accepted there was no fraudulent intent in the taking of the drug. So why no No Significant Fault mitigation? Because a separate tampering charge followed, and the standard tampering sanction is four years.

There is a paradox here and I will not bury it. A forged document is itself circumstantial proof of an intent to conceal. Yet it did not escalate the presence sanction; it added four years as a separate charge. The panel weighed the two offences separately, and that weighing is legally coherent.

The real question is where the available defence went. S9 glucocorticoids are prohibited in-competition only. In road racing the in-competition testing window opens at 23:59 the day before the race. Had the knee injection been given days earlier with attention to the route-specific washout period, there would have been no case at all. Had genuine medical records existed, route and timing could have been argued and the case might have collapsed into a light sanction. A Therapeutic Use Exemption was also open. Nobody took that path. A forged prescription was produced, and the one defence that could have worked was the one destroyed.

A caveat on the numbers: the pharmacology is settled, but the exact testing-window and washout figures I am citing are data pending verification. I built the desk before I trusted the table, and that order holds.

Now the part nobody looked at: the payroll beneath this case. Ethiopian road running has no professional contract, only race-to-race appearance fees. The World Marathon Majors and Asia's label races — China's especially — are the most reliable income tier for elite Ethiopian and Kenyan fields. It is also the tier where AIU testing yields most. Two economies, the fee economy and the testing economy, are colliding inside the same races.

The other end of that collision is medical support. A 2:18-class marathoner who races two or three times a year is often not travelling with a credentialed team physician. Masking injury pain is economically rational — miss the race, miss the fee. Glucocorticoids are the cheapest, most available tool for that job. Where there is no TUE infrastructure, paperwork gets improvised.

Aga's record. The source gives no personal best. The figures usually cited from public records — 2:18:34 in Berlin 2026 for second, and 2:20:40 in Tokyo 2026 for first — are data pending verification, so I keep them in parentheses rather than as claims. What is established: the 2026 Tokyo Marathon title, and three second-place finishes at World Marathon Majors. That profile leaves no room for confusion — she was genuinely elite.

The age line is just as clear. Age 32, a six-year ban, a return age of roughly 38. Ethiopia's women's marathon depth is such that a 2:18 performer is not automatically selectable; a 38-year-old returning with a doping record is effectively unselectable. The ban reads as six years on paper and a career in effect.

One thing I will state plainly, because it is my habit: no mark from that Chinese half marathon appears in the source. 'She won, so the form was good' is an inference, not a measurement. The win tells us the field was elite enough to be tested. That is all.

Contrarian: is the six years for the injury, or for the paper?

Here is where I have to fight my own reflex.

A six-year ban over a substance with no established endurance benefit will be recruited for two opposite conclusions. One camp will say: see how rigorous the AIU is. The other will say: disproportionate enforcement against African road runners. I will treat neither as comfortable truth, and not out of even-handedness. The cause has to be separated from the fact.

The fact is settled — a ban exists, the documents were found to be forged. That line gets written as a finding, not as a debate. The debate is over cause: was this outcome about the drug or about the paper? My reading of the arithmetic says the paper. And if the cause is the paper, then reading the length of the ban as proof of anti-doping severity is a mistake. It is document-verification severity, not pharmacology severity. The numbers were clean; the story underneath them was not.

Second point, one I keep repeating: correlation is not causation. One Ethiopian marathoner's prescription proved fake — that does not establish that every athlete in her training cluster is fabricating paper. But it is also true that the informal medical network serving one athlete usually serves several in the same cluster. There may be more cases in the pipeline. That is an inference, not an accusation, and I will not write it as one.

Third: the knee. Chronic knee pathology is a known load-bearing failure mode in high-mileage marathoners. If the injury is a years-long problem rather than a March event, then what we are calling one athlete's dishonesty is in fact a symptom of an absent system — no doctor, no TUE pathway, no support staff to steer an athlete away from fabricating a document. I will not complete that claim, because the data to prove it is not in front of me. Nor will I take the comfort of 'everyone is guilty' — just as, after 2026, I accepted neither the clean golden age nor wholesale damnation. Write the date, name the mechanism, keep the era open.

What to watch

Three signals, three clocks, one open question.

The appeal window is typically around 21 days from the reasoned decision. A document-based finding is hard to overturn, so an appeal is legally available and practically unlikely. Second: a clinic that does not exist points to document forgery, and that sits outside AIU jurisdiction. Whether national authorities take it up is the least-covered and most consequential part of this file. Third: the enforcement frontier is shifting from detection to verification. If more cases repeat out of the same training cluster in the coming months, that is a pattern, not an outlier. I don't chase outliers; I wait for them to repeat.

And the question I cannot answer: if methylprednisolone has no proven effect on race outcomes, is this six-year ban for the injury an athlete was treating herself, or for the paper she signed on someone else's word? Which of the two is being punished here is something athletics will settle over the next few years.